Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2020-09-24 Earnings Release
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma meddelar positiva resultat från den prövarinitierade fas 2-studien med imlifidase för behandling av anti-GBM sjukdom
Earnings Release Classification · 99% confidence The document is titled 'PRESSMEDDELANDE' (Press Release) and announces positive results from a Phase 2 clinical trial for the drug imlifidase concerning anti-GBM disease. It includes key data points, quotes from management/investor relations, and concludes with a statement that the information is required to be made public under the EU Market Abuse Regulation (MAR). This format is characteristic of an immediate, material corporate announcement, often released outside of standard quarterly/annual filings. While it contains financial/operational news, it is not a full financial report (10-K, IR), an earnings release (ER) focused only on summary figures, or a management discussion (MDA). It is a specific regulatory disclosure concerning clinical progress. Given the options, this type of material announcement, especially one referencing MAR disclosure requirements, fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory public disclosure that doesn't fit the more specific financial or governance codes. It is not an announcement of a report publication (RPA), but the news itself. FY 2020
2020-09-24 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for a specific holder, Redmile Group, LLC, in Hansa Biopharma AB. It explicitly states 'Reason for major shareholding notification Buy' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage (5.20829%). This structure is characteristic of a notification regarding a significant change in ownership, which corresponds to the Major Shareholding Notification category.
2020-09-09 English
Hansa Biopharma ger uppdatering om kliniska program
Regulatory Filings Classification · 95% confidence The document is a press release dated September 1, 2020, providing updates on clinical programs (Idefirix/imlifidase), timelines affected by COVID-19, and upcoming milestones. It explicitly states that the information is subject to disclosure under the EU Market Abuse Regulation (MAR) and is released via investor relations contacts. This format—a formal announcement detailing operational and clinical progress, often timed around investor events—is characteristic of an Earnings Release (ER) or a general operational update. Since it focuses on clinical trial progress and commercial launch timelines rather than comprehensive financial statements (like a 10-K or IR) or just management changes (MANG), it fits best as an Earnings Release (ER) which typically includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less structured. Given the structure detailing key updates and future milestones, ER is the most appropriate fit for a periodic operational/clinical update preceding or following a financial period, even if it's not explicitly labeled 'Quarterly Results'. It is not a transcript (CT), a formal annual report (10-K), or a simple announcement of a report (RPA).
2020-09-01 Swedish
Hansa Biopharma provides updated guidance on its clinical programs
Regulatory Filings Classification · 100% confidence The document is titled "PRESS RELEASE" and provides an update on clinical programs, regulatory approvals (EU Commission for IdefirixTM), and revised timelines due to COVID-19 impacts. It includes specific future milestones (Q3 2020, Q4 2020, H1 2021, etc.) and concludes with a statement that the information is made public pursuant to the EU Market Abuse Regulation (MAR). This structure—a formal announcement detailing operational and clinical progress, often released outside of standard quarterly filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on operational updates and guidance rather than just financial results highlights (ER) or a general regulatory filing fallback (RNS), and given the context of updating clinical timelines and milestones, it functions as a key operational update. However, because it is a press release providing guidance updates and clinical progress, it most closely aligns with the function of an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it doesn't fit ER perfectly. Given the focus on updating guidance and clinical timelines, ER is a strong candidate, but RNS is the safest fallback for non-standard, mandatory disclosures like MAR announcements that aren't strictly financial results. Since it is a press release updating guidance and clinical status, it is often categorized as an Earnings Release (ER) if it accompanies or precedes formal earnings, or RNS if it's purely operational/regulatory news. Given the content is a mix of operational updates and guidance, and it's explicitly mandated by MAR, RNS is the most appropriate general regulatory category for non-standard announcements, although ER is plausible if this was released near a reporting period. I will classify it as RNS as it is a general regulatory announcement mandated by MAR.
2020-09-01 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for an entity named 'Nexttobe AB' concerning 'Hansa Biopharma AB'. It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures for shares and voting rights, including the resulting percentage (4.831%). This structure is characteristic of a notification regarding a significant change in ownership, which aligns directly with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2020-08-31 English
The EU Commission grants conditional approval for Idefirix[TM] (imlifidase) in highly sensitized kidney transplant patients in the European Union
Regulatory Filings Classification · 95% confidence The document is a 'PRESS RELEASE' announcing that the 'EU Commission grants conditional approval for IdefirixTM'. It details a significant corporate event (first drug approval, transition to commercial stage) and includes contact information for Investor Relations and Corporate Communications. This type of announcement, which is a formal communication of a major business development, fits best under the general category for regulatory or significant corporate announcements that are not specific financial reports (10-K, IR, ER) or management changes (MANG). Since it is a formal announcement mandated under EU Market Abuse Regulation (MAR) but doesn't fit the specific definitions for ER, CAP, or MANG, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements.
2020-08-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.